Citations

Clear

9550 citation(s) found for "James, EM".

Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors
Wang, Guangfeng , Wang, Jiawan , Zhang, Xiaochun, Yang, Liuzhan , Oztosun, Gorkem, Sears, James J., Xiao, Ke , Garana, Belinda B., Zoberi, Mark I., Bektas, Aaron U., Coma, Silvia, Pachter, Jonathan A. , Gosline, Sara JC, Pratilas, Christine A. , Szymanski, Jeffrey J. , Borcherding, Dana C. , Zhang, Xiaochun, Oztosun, Gorkem , Sears, James J. , Garana, Belinda B. , Rathore, Richa , Coma, Silvia, Gosline, Sara J.C. , Hirbe, Angela C.

Mayo Clinic

Journal of Clinical Investigation | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1172/jci201331 | PMID 42579369 Get It

Aneuploidy is a hallmark of cancer often associated with inferior prognosis. Copy number gains of chromosome 8 (chr8) are recurrent in multiple cancers, including breast, prostate, colorectal cancers, and sarcomas such as malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are aggressive, hard-to-treat sarcomas frequently linked to the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome. To investigate the role of chr8 gain in MPNST pathogenesis, we performed a CRISPR knockout screen and identified 58 essential genes on chr8, including PTK2, which encodes focal adhesion kinase (FAK). We evaluated FAK as a therapeutic target and tested small-molecule FAK inhibitors (FAKi) alone or combined with RAF/MEK inhibitors (RAF/MEKi), a class of agents relevant to NF1-deficient tumors with ERK pathway hyperactivation. Both pharmacological and genetic inhibition of FAK reduced MPNST cell proliferation in vitro and tumor growth in vivo. Combined FAKi and RAF/MEKi treatment further suppressed phosphorylation of FAK, STAT3, and AKT while increasing cleaved caspase-3 and PARP-1, indicating enhanced apoptosis. In MPNST patient-derived xenograft (PDX) models, combination therapy significantly reduced tumor growth, showing superior efficacy, particularly in chr8 gain MPNST-PDX. These results support FAK/RAF/MEK co-targeting as a promising therapeutic strategy for chr8 gain MPNST and related tumors.
Public health AI’s precision strategy: Globally integrating, institutionalizing, and scaling science, economics, and ethics
Anavekar, Nandan, Omutoko, Lillian , Oduor, Patience, Kokonya, Donald , Rayel, John James, Sotomayor, Claudia, Sinyavskiy, Oleg, Aksamit, Timothy, Marshall, Gary, Grindem, David, Jarsania, Dhairya, Mackay, K. , Garcia, Alberto, Gallagher, Colleen, Best, Ryan, Petralanda, Maria Isabel Iñigo, Immanuel, Gifty, Halm, Josiah, Iliescu, Cezar, Monlezun, Dominique , Anavekar, Nandan S., Oduor, Patience , Rayel, John, Sotomayor, Claudia , Aksamit, Timothy R. , Grindem, David , Jarsania, Dhairya , MacKay, Keir, Gallagher, Colleen M. , Dugani, Sagar B. , Best, Ryan, Gunasekeran, Dinesh Visva , Wong, Tien Yin , Halm, Josiah K. , Iliescu, Cezar

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10531187/v1 Get It

Abstract Artificial intelligence is spreading through public health agencies and healthcare systems faster than workforces are trained to govern it. We describe RHAMI (Responsible Health AI Readiness and Maturity Index), the first human-centered automated composite index for health organizations to score AI readiness and maturity as one measurable system of science, economics and ethics, and the physician certification-to-Master’s pathway built to teach what it measures—both designed jointly by frontline public health professionals, clinicians, ethicists, engineers, leaders, and policy-makers in low- and middle-income countries and high-income countries.
Nonsystemic Vasculitic Neuropathy Presenting as Inflammatory Demyelinating Polyradiculoneuropathy
Zhang, Tony , Engelstad, JaNean K., Dyck, P. James B. , Engelstad, JaNean

Mayo Clinic

Journal of the Peripheral Nervous System | August 8, 2026 | Volume: 31 | Issue: 3 | Pages: No page available

10.1111/jns.70158 | PMID 42568127 Get It

ABSTRACT Background and Aims Nonsystemic vasculitic neuropathy classically presents as a painful asymmetric axonal neuropathy, multiple mononeuropathies or radiculoplexus neuropathy. Demyelinating electrophysiologic features are rare and may lead to misdiagnosis. We describe a patient with biopsy‐proven vasculitic neuropathy presenting as a severe symmetric demyelinating polyradiculoneuropathy. Methods Clinical, electrophysiologic, imaging, laboratory, and histopathologic findings are presented. Results A 57‐year‐old man developed acute ascending weakness, sensory loss, facial weakness, and areflexia following a febrile illness, with initial improvement before developing recurrent neurological decline 6 weeks after initial symptom onset despite treatment with intravenous immunoglobulin and plasma exchange. Cerebrospinal fluid protein was elevated. Nerve conduction studies demonstrated prolonged distal motor latencies, slowed conduction velocities, conduction block, and prolonged blink reflex latencies, fulfilling 2021 European Academy of Neurology/Peripheral Nerve Society electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). MRI demonstrated mild but diffuse lumbosacral plexus enlargement and T2 hyperintensity. Sural nerve biopsy ultimately demonstrated evidence of epineurial inflammation and microvasculitis with ischemic nerve injury, accompanied by both increased rates of axonal degeneration (12%) and segmental demyelination (9%) on teased fiber analysis. Treatment with corticosteroids and rituximab resulted in complete neurological recovery. Interpretation Vasculitic neuropathy may closely mimic CIDP clinically, radiologically, and electrophysiologically. Clues to the vasculitis diagnosis were prominent neuropathic pain, dense denervation on electrophysiology, and poor response to typical CIDP treatment. Peripheral nerve biopsy remains a critical tool in the evaluation of atypical or treatment‐refractory inflammatory neuropathies.
Cardiac Resynchronization With or Without Defibrillator in Nonischemic Cardiomyopathy: A Nationwide Cohort Study (DECIDE-CRT)
Selvaganesan, Padmini , Karnib, Mohamad , Helmy, Irfan , Rashid, Imran, Osman, Mohammed Najeeb , Amuthan, Ram , Vest, Amanda R. , Intini, Anselma, Fang, James C. , Sahadevan, Jayakumar, Sundaram, Varun , Nishimura, Rick , Osman, Mohammed N , Amuthan, Ram , Vest, Amanda R , Intini, Anselma , Fang, James C , Cleland, John G F , Sahadevan, Jayakumar , Zakeri, Rosita , Sundaram, Varun , Reddy, Yogesh N.V. , Cleland, John G.F. , Zakeri, Rosita

Mayo Clinic

Circulation: Heart Failure | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circheartfailure.126.014213 | PMID 42565236 Get It

BACKGROUND: With evolving therapy for heart failure with reduced ejection fraction, the benefits of adding a defibrillator in patients undergoing cardiac resynchronization therapy (CRT) remain unclear, particularly for nonischemic cardiomyopathy (NICM). This study evaluates long-term survival among patients with NICM treated with CRT defibrillator (CRT-D) versus CRT pacemaker (CRT-P). METHODS: DECIDE-CRT (Cardiac Resynchronization With or Without Defibrillator in Non-Ischemic Cardiomyopathy) is a multicenter cohort study across 170 US Veterans Affairs hospitals. We identified patients with NICM receiving primary-prevention CRT-P or CRT-D between January 1, 2006, and December 31, 2020. Using a propensity score approach, we applied inverse probability of treatment weighting to balance baseline characteristics between the CRT-P and CRT-D groups. An inverse probability of treatment weighting–weighted Cox model estimated hazards for all-cause mortality. Secondary outcomes included generator replacement, device-related infections, hospitalization for heart failure, and ventricular arrhythmias. RESULTS: Of 16 609 CRT recipients, 3965 met NICM primary-prevention criteria (CRT-D=3158; CRT- P =807). At baseline, patients with NICM receiving CRT-P were much older, with more cardiovascular and noncardiovascular comorbidities compared with the CRT-D group. During the median follow-up of 5.2 years, the mortality rate for CRT-P versus CRT-D was 9.46 versus 9.21 per 100 person-years (RR, 0.97 [95% CI, 0.71–1.13]; P =0.66). The adjusted hazard ratio for all-cause mortality using the inverse probability of treatment weighting-Cox model was 0.90 (95% CI, 0.71–1.13; P =0.34). There was no difference in adjusted hazard for heart failure hospitalization (hazard ratio, 1.27 [95% CI, 0.86–1.87]), while the CRT-D group had higher rates of generator replacement and device-related infections. CONCLUSIONS: This nationwide observational study from the Veterans Affairs Health system did not demonstrate a clear survival advantage with the addition of a defibrillator among patients with NICM receiving CRT although residual confounding cannot be excluded. Given the uncertainty surrounding the incremental benefit of the defibrillator in this setting, a randomized trial is needed to test the incremental value of CRT-D over CRT-P in NICM.
Arterial stiffness and risk of dementia in late life: The ARIC neurocognitive study
Barbee, Jenna , Wei, Jingkai , Tanaka, Hirofumi, Knopman, David S., Kucharska‐Newton, Anna, Sharrett, A. Richey, Hughes, Timothy M. , Matsushita, Kunihiro, Meyer, Michelle L., Palta, Priya, Pike, James Russell , Knopman, David S. , Kucharska‐Newton, Anna , Matsushita, Kunihiro , Mosley, Thomas H. , Meyer, Michelle L.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | August 7, 2026 | Volume: 18 | Issue: 3 | Pages: No page available

10.1002/dad2.70427 | PMID 42569008 Get It

Abstract INTRODUCTION Associations of arterial stiffness, measured through pulse wave velocity (PWV), with incident dementia may be driven by age‐related structural changes to the arterial wall or by elevated blood pressure. METHODS Dementia‐free White or Black participants in the community‐based Atherosclerosis Risk in Communities (ARIC) cohort study with measures of PWV were examined. The associations of carotid‐femoral PWV (cfPWV) and total, structural, and load‐dependent PWV with dementia were estimated using Poisson regression models and Cox proportional hazards models. Dementia cases were defined by physician‐adjudicated review, telephone interviews, hospitalization records, and death certificates. RESULTS Of 4818 participants included in the study population (mean age: 75 years; 41% male, 21% Black), 1067 (22%) developed dementia over a median follow‐up of 9.0 years. Higher cfPWV, total PWV, structural PWV, and load‐dependent PWV were associated with greater dementia risk. DISCUSSION Both structural and pressure‐related arterial stiffness mechanisms may underlie the link between PWV and dementia.
Performance of a Novel Negative Pressure Wound Therapy Filler in Wound Contraction
Mowers, Colton C., Hilsman, Joe H., Shuler, Michael S. , Fleming, James Coleman, Sarraj, Mohamed , Freedman, Brett A. , Dhodapkar, Meera M, Mowers, Colton C. , Dhodapkar, Meera M.

Mayo Clinic

Wounds: a compendium of clinical research and practice | August 6, 2026 | Volume: 38 | Issue: 8 | Pages: No page available

10.25270/wnds/26050 | PMID 42641019 Get It

Background. Negative pressure wound therapy promotes wound healing through fluid removal, edema reduction, and mechanical contraction. A novel thermoplastic elastomer (TPE) dressing has been developed to improve exudate evacuation and reduce tissue ingrowth, but its effect on wound contraction compared with reticulated open cell foam (ROCF) remains unclear. Objective. To compare the degree of wound contraction with the TPE dressing, ROCF, or no filler at different wound depths and negative pressure settings in a porcine explant model. Materials and Methods. The effect of the materials or lack thereof on wound contraction was investigated at 2 wound depths (shallow, deep) and 3 negative pressure settings (−50 mm Hg, −80 mm Hg, and −125 mm Hg). Wound width was measured at 3 standardized locations before and during therapy. Univariable and multivariable linear regression analyses were performed to identify factors associated with contraction. Results. A total of 810 measurements were obtained. Both the TPE dressing and ROCF demonstrated statistically significantly greater contraction than no filler. In deep wounds, greater contraction was noted with the TPE dressing compared with ROCF. Higher negative pressure and increased wound depth were independently associated with greater contraction. Absolute differences in contraction between dressings were small (<3 mm across all conditions). Conclusion. The TPE dressing provides equivalent or greater wound contraction compared with ROCF, particularly in deep wounds, without impairing macrodeformation. Given the small magnitude of differences, the clinical relevance of this finding likely depends on additional factors, which should be evaluated in future in vivo studies.
Management of Crohn’s Disease in Adult Patients: A Contemporary Surgical Perspective
Delabays, Constant , Zhu, Emilie , Kefleyesus, Amaniel , Perry, William, Ansell, James , Schoepfer, Alain, Grass, Fabian , Grass, F , Perry, William , Schoepfer, Alain

Mayo Clinic

Biomedicines | August 6, 2026 | Volume: 14 | Issue: 8 | Pages: 1774

10.3390/biomedicines14081774 | PMID 42652157 Get It

Introduction: Crohn’s disease (CD) remains associated with long-term morbidity despite biologic therapies. Surgery, historically considered a last-resort option, is increasingly integrated into disease management earlier. This review examines the evolving role of surgery in the biologic era. Methods: A focused narrative review of randomized controlled trials, meta-analyses, observational studies, and international guidelines addressing contemporary surgical strategies in CD was performed. Results: The LIR!C trial demonstrated that early ileocecal resection provides durable remission and improves long-term outcomes compared with biologic therapy in selected patients. The PISA II trial supported an early combined surgical and medical approach for perianal fistulizing disease. Preoperative optimization, including nutritional support and adjustment of immunosuppressive therapy, has become a cornerstone of perioperative management. Laparoscopic surgery remains the preferred approach whenever feasible, while robotic surgery is emerging as a promising platform that is expected to play an increasingly important role in the surgical management of CD. Postoperative recurrence remains a major challenge, prompting the development of innovative surgical strategies. Although the Kono-S anastomosis initially showed promising reductions in recurrence, recent prospective studies failed to confirm superiority over conventional techniques. Similarly, extended mesenteric excision did not demonstrate improved outcomes despite increasing evidence implicating the mesentery in CD pathogenesis. Strictureplasty remains an effective option for selected fibrotic small-bowel strictures. Conclusions: Surgery remains central to multidisciplinary CD management and offers the potential to modify disease when performed early in selected patients. The impact of innovative surgical strategies on postoperative recurrence remains uncertain, and ongoing trials are expected to further help with surgical decision-making.
Juvenile Parkinson's disease: Symptom burden and treatment challenges
Malfer, Lorenzo , Piat, Capucine , Uitti, Ryan J., Fugoso, Leonardo G., Bower, James H. , Savica, Rodolfo , Coffman, Keith A, Savica, Rodolfo , Mullan, Aidan F. , Uitti, Ryan J. , Fugoso, Leonardo, Coon, Elizabeth A. , Coffman, Keith A.

Mayo Clinic

Journal of Parkinson’s Disease | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/1877718x261473047 | PMID 42555091 Get It

Juvenile Parkinson's disease (JPD) is a rare condition characterized by the onset of parkinsonian motor symptoms before the age of 21. Sixteen patients with JPD who presented to the Mayo Clinic between 1990-2020 were included. The median age of symptoms onset was 18.5 years, and six cases had pathogenic PRKN mutations. Resting tremor was the most frequent initial symptom (81.3%), and non-motor symptoms were notably common, including mild cognitive impairment (56.3%), anxiety (62.5%), and depression (56.3%). Levodopa responsiveness was suboptimal in 9 patients and 14 exhibited motor fluctuations. JPD demonstrates distinct clinical characteristics compared with early-onset and late-onset PD.
Higher systemic AL amyloidosis scores at diagnosis predict development of new-onset atrial fibrillation or flutter
Palma-Grisi, J Di, Hazaveh, S, Weiss, Y, Yu, J, Vandyck-Acquah, M, Parmar, H, Palma-Grisi, James Di , Hazaveh, Sara , Vandyck‐Acquah, Marian

Mayo Clinic

European Heart Journal Supplements | August 3, 2026 | Volume: 28 | Issue: Supplement_8 | Pages: No page available

10.1093/eurheartjsupp/suag097.057 Get It

Abstract Background Light chain cardiac amyloidosis (AL-CM) is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Early diagnosis and risk stratification is critical for prognostication and management, particularly identifying patients most likely to need heart transplants. The systemic light chain amyloidosis (sAL) score is derived from echocardiographic parameters: relative wall thickness (RWT), E/e' ratio, global longitudinal strain (GLS), and tricuspid annular plane systolic excursion (TAPSE) and is validated in the diagnosis of AL-CM [1]. Its prognostic value for development of atrial fibrillation, progression of heart failure, and hospitalizations remains unclear. This study evaluates the association between the sAL score, arrhythmias, and functional outcomes in patients with confirmed AL-CM. Methods A retrospective review of patients seen at our hospital, with confirmed AL-CM diagnosed between June 2014 and October 2021 was conducted on an IRB-approved protocol. The sAL score was collected at the time of diagnosis. Binary outcomes were evaluated using a weighted Mann-Whitney U test, with effect size calculated as r=Z/sqrt(N). Ordinal and continuous outcomes were analysed using weighted Spearman correlation, with Spearman’s rho reported as the effect size. Results 37 patients with AL-CM were included (51.4% male), with a median age of 70 years [IQR 66–76], a median sAL score of 5 [IQR 3–6], and a median left ventricular ejection fraction (LVEF) of 55% [IQR 50–60] at diagnosis. 24 patients had their AL-CM diagnosed by cardiac MRI and positive Congo red on peripheral biopsy (e.g., fat pad); the other 13 had positive endomyocardial biopsy. 22 patients had sAL scores ≥ 5 with overall survival of 17/22 (77.3%) and median follow-up of 53 months. 15 patients had sAL scores &lt; 5 with overall survival of 14/15 (93.3%) and median follow-up of 57 months. 4 patients had atrial fibrillation or flutter at diagnosis. 6 patients developed atrial fibrillation or flutter with a median onset of 15 months after diagnosis. Higher sAL scores at diagnosis were associated with development of new-onset atrial fibrillation or flutter (median sAL 4.5 vs 5, p = 5.75×10^-10, r = 1.02), heart failure hospitalizations (median sAL 5 vs 5, p = 1.94×10^-6, r = 0.78), and ≥30% eGFR decline at 12 months (median sAL 4.5 vs 6, p=8.69×10^-24, r = 1.65). Higher sAL scores were moderately correlated with NYHA class (rho = 0.44, p = 0.00378) and strongly correlated with diastolic dysfunction grade (rho = 0.549, p = 9.99×10^-6) but not associated with change in LVEF (p = 0.51 and p = 0.62, respectively). Conclusion sAL scores of ≥5 at diagnosis were associated with worse functional and clinical outcomes in patients with proven AL-CM. These findings suggest the sAL score predicts electrophysiological changes, supporting its potential role in early risk stratification and disease monitoring.
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas
Mondello, Patrizia , Sadekova, Alisa , fede, ksenia, Dasari, Surendra , Au, Wesley , Kriukov, Kirill , Meerson, Mark, Novak, Joseph, Yang, Zhi-Zhang , Gysbers, Brianna J. , Villasboas, Jose, Wiebe, Daniil S. , Shvyrkova, Anastasiia, Margaryan, Sargis, Nesmelov, Alexander, Sarachakov, Aleksander, Petrosyants, Arman, Bagaev, Alexander , Novak, Anne J. , Casulo, Carla, Hsi, Eric, Fowler, Nathan, King, Rebecca, Singh, Harinder, Armand, Philippe, Pasqualucci, Laura, Ansell, Stephen M. , Binder, Moritz , Yang, Zhi-Zhang , Gysbers, Brianna J , Postovalova, Ekaterina , Wiebe, Daniil , Kotlov, Nikita , Wang, Yucai , Novak, Anne J , Habermann, Thomas , Maurer, Matthew , Cerhan, James R , Shlomchik, Mark , Ansell, Stephen M , Mondello, Patrizia , Dasari, Surendra , Au, Wesley, Binder, Moritz , Meerson, Mark , Novak, Joseph P. , Villasboas, José C. , Guzman, Emmanuel Contreras , Nesmelov, Alexander, Wang, Yucai , Habermann, Thomas M. , Hsi, Eric D. , Maurer, Matthew J. , Cerhan, James R. , Singh, Harinder, Armand, P., Pasqualucci, Laura , Burack, Richard

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10435263/v1 | PMID 42620132 Get It

Abstract Germinal center (GC)-derived lymphomas arise within a specialized immune ecosystem, yet whether malignant cells direct its remodeling remains unclear. Integrating genomic, transcriptomic, spatial, and functional analyses across follicular lymphoma and diffuse large B-cell lymphoma, we define a developmental framework linking malignant B-cell differentiation state to tumor microenvironment (TME) organization. Rather than segregating by histology, lymphomas align along a shared differentiation continuum in which proliferative dark zone (DZ) states associate with immune-depleted TMEs, whereas post-GC/memory B-cell (MBC) states drive inflamed but immunosuppressed TMEs. Spatial profiling reveals collapse of GC architecture and emergence of suppressive myeloid niches along this trajectory. Single-cell lineage reconstruction uncovers a DZ-to-MBC developmental axis underlying lymphoma evolution. Genetic reprogramming in vivo demonstrates that malignant differentiation state is sufficient to instruct TME remodeling. Collectively, these findings establish malignant differentiation state as a causal determinant of immune architecture across GC-derived lymphomas and identify lineage-directed immune reprogramming as a potential therapeutic strategy.